Ignite Creation Date:
2024-10-25 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06529588
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-06-18
Brief Title:
Estimation of suPAR in Chronic Periodontitis With Post-radiotherapy on HNCs Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Soluble Urokinase Plasminogen Activator Receptor suPAR is a Potential Biomarker of Stage III-IV Grade C Periodontitis Through the Impact of Post-radiotherapy on Head and Neck Cancer Patients
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HNCs
Brief Summary:
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy HNC post-RT
Detailed Description:
The urokinase-type plasminogen activator receptor uPAR plays an essential function in leukocytes and endothelial homeostasis and therefore in the development of chronic periodontitis The study enrolled 150 participants 50 chronic periodontitis with head and neck cancer post radiotherapy CPHNC post-RT patients 50 chronic periodontitis CP without HNC patients and 50 healthy controls Clinical Attachment Loss CAL Probing Pocket Depth PPD Plaque Index PI and Gingival Bleeding Index GBI were recorded An enzyme-linked immunosorbent assay ELISA was constructed to quantify serum suPAR levels
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None